LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | - | - | - | - |
| Other costs and expenses | - | - | 293,158 | 428,482 |
| Legal fees relating to patents and licensing | - | - | 45,416 | 63,612 |
| Research and development costs | 60,648 | 91,457 | 361,630 | 210,708 |
| General and administrative costs | 714,161 | 615,483 | 283,053 | 306,354 |
| Total costs and expenses | 774,809 | 706,940 | 983,257 | 1,009,156 |
| Loss from operations | -774,809 | -706,940 | -983,257 | -1,009,156 |
| Interest income | 365 | 441 | 1,437 | 2,233 |
| Interest expense | 1,810 | 3,135 | 1,049 | 4,154 |
| Foreign currency gain | 581 | 79 | -3,161 | 158 |
| Net loss | -775,673 | -709,555 | -986,030 | -1,010,919 |
| Net loss per common share basic | -0.29 | -0.29 | -0.44 | -0.45 |
| Net loss per common share diluted | -0.29 | -0.29 | -0.44 | -0.45 |
| Weighted average common shares outstanding basic | 2,720,533 | 2,471,513 | 2,249,290 | 2,249,290 |
| Weighted average common shares outstanding diluted | 2,720,533 | 2,471,513 | 2,249,290 | 2,249,290 |